Yuji Otsuki
Chief Executive Officer FerroptoCure
Seminars
Tuesday 19th May 2026
Biomarker Strategy in the Clinical Development of Ferroptosis-Based Cancer Therapy
12:20 pm
- Overview of FerroptoCure’s biomarker strategy to support the clinical development of ferroptosis-based cancer therapies
- Current progress and future direction in identifying biomarkers for pharmacodynamic response and clinical utility in refractory cancers such as TNBC
